BARCELONA, Spain--(BUSINESS WIRE)--Medtronic (NYSE:MDT) today presented new long-term data from the ENDEAVOR clinical trial program reinforcing the existing safety and efficacy profile of the Endeavor® drug-eluting coronary stent system. Four-year results from the 100-patient first-in-man ENDEAVOR I trial and three-year results from the nearly 1,200 patient ENDEAVOR II trial demonstrate that Endeavor is associated with sustained safety, significant reductions in repeat procedures and no late stent thrombosis in either trial using the pre-specified trial protocol definitions. The ENDEAVOR II study also showed that the Medtronic Driver® bare metal stent offers consistent and durable long-term clinical results.
